Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) were up 1.2% during trading on Wednesday . The stock traded as high as $820.72 and last traded at $816.88. Approximately 949,491 shares traded hands during trading, a decline of 76% from the average daily volume of 3,943,837 shares. The stock had previously closed at $807.19.
Wall Street Analyst Weigh In
Several analysts have commented on LLY shares. Guggenheim restated a "buy" rating on shares of Eli Lilly and Company in a report on Friday, May 23rd. HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their target price for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price objective for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.37.
View Our Latest Stock Report on LLY
Eli Lilly and Company Stock Performance
The stock's 50-day moving average price is $771.74 and its 200-day moving average price is $800.91. The company has a market cap of $769.20 billion, a P/E ratio of 69.31, a PEG ratio of 1.40 and a beta of 0.41. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the prior year, the company earned $2.58 EPS. The company's revenue for the quarter was up 45.2% compared to the same quarter last year. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.
Eli Lilly and Company Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.74%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company's payout ratio is 48.82%.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of LLY. Kondo Wealth Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the first quarter valued at approximately $205,000. First Long Island Investors LLC increased its stake in shares of Eli Lilly and Company by 14.1% in the first quarter. First Long Island Investors LLC now owns 27,020 shares of the company's stock valued at $22,316,000 after buying an additional 3,336 shares during the period. eCIO Inc. acquired a new position in shares of Eli Lilly and Company in the first quarter valued at approximately $732,000. Harold Davidson & Associates Inc. increased its stake in shares of Eli Lilly and Company by 1.0% in the first quarter. Harold Davidson & Associates Inc. now owns 4,084 shares of the company's stock valued at $3,373,000 after buying an additional 42 shares during the period. Finally, CBIZ Investment Advisory Services LLC increased its stake in shares of Eli Lilly and Company by 14.2% in the first quarter. CBIZ Investment Advisory Services LLC now owns 548 shares of the company's stock valued at $453,000 after buying an additional 68 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.
Eli Lilly and Company Company Profile
(
Get Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
See Also
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
